Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
A new study found no racial or ethnic disparities in prior authorization outcomes for Black and Hispanic patients, but Asian patients had higher rates of approvals compared to White patients. The study analyzed data from 18,041 cancer patients diagnosed between 2017 and 2020.
A new clinical algorithm developed at the University of Gothenburg can accurately identify highly aggressive forms of basal cell carcinoma. The algorithm uses a combination of clinical and dermoscopic images to distinguish between low-risk and high-risk tumors, allowing for more effective treatment and better patient outcomes.
Researchers analyzed collision-type mixed ductal-lobular breast cancers and found that IDC and ILC regions had distinct gene expression profiles. The study reveals tremendous variation within this already highly variable disease, highlighting the need for personalized treatments.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
Scientists have developed a new immunotherapy that can identify and fight cancer cells in patients with Merkel cell carcinoma. The treatment involves stimulating the immune system's T cells against specific elements of the virus involved in cancer formation.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Researchers have developed a new imaging technique that rapidly and accurately identifies cancerous tissues in breast samples. The method uses machine learning algorithms trained on hyperspectral dark-field microscopy data to pinpoint regions of invasive ductal carcinoma and invasive mucinous carcinoma.
A massive study identifies new biomarkers for renal cell carcinoma subtypes, improving diagnosis and treatment. The researchers' integrative analysis of proteogenomic datasets reveals molecular features shared by clear cell and non-clear cell RCC tumors, as well as unique features to various subtypes.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
Researchers identified a new PD-1 immune checkpoint mechanism promoting merkel cell carcinoma growth. MCC cells express PD-1 and its receptor binding accelerates tumor growth via mTOR pathway activation.
A study of 4,819 women with benign breast disease found an increased risk of breast cancer compared to the general population. The study's findings suggest that pathologic classifications could improve breast cancer risk stratification.
A deep learning AI model developed using mammographic images alone accurately predicted both ductal carcinoma in situ (DCIS) and invasive carcinoma, showing no bias across multiple races. The model outperformed traditional risk models in predicting breast cancer risk, providing a more accurate and equitable assessment.
Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
Researchers identified new biological markers and pathways to develop improved therapies for endometrial cancer. The study found that in-frame indels in the PIK3R1-AKT pathway promote tumor growth and provide potential targets for controlling or stopping cancer progression.
A new AI software has achieved a 100% detection rate for melanoma, significantly improving skin cancer detection accuracy. The software correctly identified 99.5% of all skin cancers and 92.5% of pre-cancerous lesions, with potential to reduce face-to-face consultations and enhance dermatology triage.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
A new size threshold for retropharyngeal lymph nodes is proposed to improve risk stratification and treatment decisions in patients with nasopharyngeal carcinoma. Using a 6-mm threshold, the study found significant differences in overall survival between stage-I and stage-II disease.
Researchers identified distinct genomic characteristics that impact prognosis for patients with triple negative apocrine carcinoma. The study confirmed a five-year disease-free survival rate of 92.2% for these patients, significantly higher than those diagnosed with other types of TNBC.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A new study shows that estrogen receptor (ER) expression in ductal carcinoma in situ (DCIS) is multi-clonal, meaning it varies across different cells. This finding has significant clinical implications, as it may help avoid overtreatment and undertreatment in DCIS patients.
Researchers developed a reinforcement learning model that incorporates human decision-making criteria to improve AI accuracy in skin cancer diagnoses. The study showed increased sensitivity for melanoma and basal cell carcinoma, leading to more accurate diagnoses and optimal treatment decisions.
Researchers have discovered how MCV initiates DNA replication in host cells, allowing the virus to make hundreds of new copies of itself. This process is different from normal cellular DNA replication and can lead to cancer if not controlled.
Researchers found that healthy breast adipocytes secrete IGFBP2, which acts as a barrier against invasive breast cancer progression. Lower IGFBP2 levels with age may contribute to increased breast cancer risk.
A study published in the Journal of the American Academy of Dermatology found that curettage and cryosurgery is an effective and safe treatment method for basal cell carcinoma. The procedure involves scraping the lesion with a curette followed by freezing, resulting in good outcomes with minimal side effects.
The study shows that zolbetuximab delays tumor progression and improves overall survival by 25% compared to chemotherapy alone. Patients with CLDN18.2-positive tumors responded well to the treatment, indicating a new clinically relevant biomarker for gastric cancer.
The LY6 gene family has been found to be overexpressed in uterine corpus endometrial carcinoma (UCEC), leading to poor patient survival. Several LY6 genes have been identified as potential tumor-associated antigens and biomarkers for UCEC detection and prognosis.
Researchers developed a method to predict DCIS progression to invasive breast cancer using mice with human DCIS cells. The study found molecular similarities between humans and mice, including the presence of HER2 protein increasing breast cancer risk.
Researchers discuss the importance of biomarkers in breast lump management, enabling patients to make informed decisions between proactive treatment and watchful waiting. The development of biomarkers could provide personalized risk assessments and guide treatment strategies for women with breast lumps.
An international study of 1,044 patients with head and neck squamous cell carcinoma found that combining radiotherapy with chemotherapy significantly improves survival rates compared to radiotherapy alone. The benefit was particularly notable in patients between 65-79 years old with good general health.
The USPSTF finds the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer. Skin cancer is the most commonly diagnosed cancer in the U.S., with melanomas causing the most skin cancer deaths.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
A recent study suggests that routine evaluation of HER2 expression in ductal carcinoma in situ (DCIS) is crucial to avoid under or overtreatment. The research found a significant association between HER2 overexpression and a higher risk of recurrence, as well as improved radiotherapy outcomes.
Ultrafast MRI provides beneficial information for predicting DCIS upgrade to invasive cancer, including time to enhancement and lesion size. A study found that UF-MRI can accurately predict lesions diagnosed as DCIS at percutaneous biopsy that will be upgraded to invasive cancer at surgery.
Researchers from prominent institutions discuss hepatocellular carcinoma's pathogenesis, genomic heterogeneity, and targeted therapy options. The review aims to characterize HCC's complexities and develop clinically relevant biomarkers for better management.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
For adrenal lesions evaluated by single-phase dual-energy CT, fat fraction had significantly higher sensitivity than virtual noncontrast attenuation at both clinically optimal threshold and traditional ≤10 HU threshold. Fat fraction-derived metrics can help definitively diagnose incidental adrenal lesions as adenomas.
Researchers at Goethe University Frankfurt found that dying colon cancer cells release ATP to neighboring tumor cells, activating a survival signaling pathway. Interrupting this communication can significantly increase the effectiveness of chemotherapy against resistant tumors.
Researchers identified genes associated with aggressive clear cell renal carcinoma, a subtype of kidney cancer. Anticoagulant therapies may enhance cancer treatment efficacy. Specific genes involved in blood clotting and insulin transport were found to be linked to disease progression.
Researchers at Clinica Universidad de Navarra found that ultrasound-guided surgery (IOUS) is more effective and quicker than traditional wire-localisation methods for treating ductal carcinoma in situ (DCIS). This technique reduces the risk of positive margins, a common cause of second operations.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
The PROSPER RCC trial showed no difference in recurrence-free survival between arms, with higher adverse events reported in the nivolumab arm. The trial's results inform future research on neoadjuvant trials in high-risk renal cell carcinoma.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
A prospective study compared CEM and MRI for NAT response assessment in patients with breast cancer. CEM yielded comparable assessments of lesion size and RECIST categories as MRI, but with lower sensitivity for pathologic complete response. Delayed CEM acquisition detected residual ductal carcinoma in situ (DCIS).
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
A phase II clinical trial of remetinostat gel found a 69.7% response rate to the topical treatment, with complete responses observed across multiple BCC subtypes, and a durable response in nodular BCCs.
Cells undergoing EMT promote tumor growth by acquiring an endothelial phenotype or contributing to vascular transdifferentiation. FOXC2 is crucial for these processes.
Researchers at Jiangnan University developed a sensing platform to detect microRNA-205, a potential biomarker for radiation-resistant nasopharyngeal carcinoma. The method shows high sensitivity and excellent selectivity, enabling detection of miR-205 with a limit of detection of 4.78 nM.
Researchers from Queen Mary University of London confirmed the role of oestrogen receptor biomarker in ductal carcinoma in situ and developed a new, more accurate method to predict long-term outcomes. The study found ER expression is a strong prognostic factor for recurrence in DCIS.